Iovance Biotherapeutics Investor Presentation — March 2021

Document content

Tumor Infiltrating Lymphocyte Cell

Therapy for Treatment of Solid Tumors

© 2021, Iovance Biotherapeutics, Inc 1Forward Looking Statements

2Certain matters discussed inthispresentation are“forward -looking statements” ofIovance Biotherapeutics, Inc,Inc.(hereinafter referred toasthe“Company,” “we,”

“us,” or“our”) within themeaning ofthePrivate Securities Litigation Reform Actof1995 (the“PSLRA”) .Allsuch written ororalstatements made inthispresentation,

other than statements ofhistorical fact, areforward -looking statements andareintended tobecovered bythesafe harbor forforward- looking statements provided by

thePSLRA. Without limiting theforegoing, wemay, insome cases, use terms such as“predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,”

“expects,” “plans,” “intends,” “forecast,” “guidance,” “outlook,” “may,” “could,” “might,” “will,” “should” orother words that convey uncertainty offuture events or

outcomes and areintended toidentify forward -looking statements .Forward- looking statements arebased onassumptions and assessments made inlight of

management’s experience andperception ofhistorical trends, current conditions, expected future developments andother factors believed tobeappropriate. Forward-

looking statements inthispress release aremade asofthedate ofthispress release, andweundertake noduty toupdate orrevise anysuch statements, whether as

aresult ofnew information, future events orotherwise. Forward -looking statements arenotguarantees offuture performance andaresubject torisks, uncertainties

andother factors, many ofwhich areoutside ofourcontrol, thatmay cause actual results, levels ofactivity, performance, achievements anddevelopments tobe

materially different from those expressed inorimplied bythese forward -looking statements .Important factors that could cause actual results, developments and

business decisions todiffer materially from forward -looking statements aredescribed inthesections titled “Risk Factors“ inourfilings with theSecurities and

Exchange Commission, including ourmost recent Annual Report onForm 10-KandQuarterly Reports onForm 10-Q,andinclude, butarenotlimited to,thefollowing

substantial known andunknown risks anduncertainties inherent inourbusiness :theeffects oftheCOVID- 19pandemic ;risks related tothetiming ofandourability to

successfully develop, submit, obtain andmaintain U.S.Food andDrug Administration (“FDA”) orother regulatory authority approval of,orother action withrespect to,

ourproduct candidates, and ourability tosuccessfully commercialize anyproduct candidates forwhich weobtain FDA approval ;preliminary and interim clinical

results, which may include efficacy andsafety results, from ongoing clinical trials may notbereflected inthefinal analyses ofourongoing clinical trials orsubgroups